{"id":"cdi-31244","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL5549977","moleculeType":null,"molecularWeight":"388.47"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CDI-31244 works by binding to the SARS-CoV-2 main protease, which is essential for the viral replication. This binding prevents the protease from processing the viral polyprotein, ultimately inhibiting the replication of the virus. As a result, CDI-31244 has the potential to treat COVID-19.","oneSentence":"CDI-31244 is a small molecule inhibitor targeting the SARS-CoV-2 main protease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:50:14.786Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of COVID-19"}]},"trialDetails":[{"nctId":"NCT03501550","phase":"PHASE2","title":"Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)","status":"COMPLETED","sponsor":"Cocrystal Pharma, Inc.","startDate":"2018-06-26","conditions":"Chronic Hepatitis C","enrollment":12},{"nctId":"NCT02760758","phase":"PHASE1","title":"A Study of CDI-31244: A Novel NNI in HV and HCV Infected Subjects","status":"COMPLETED","sponsor":"Cocrystal Pharma, Inc.","startDate":"2016-04","conditions":"Hepatitis C","enrollment":76},{"nctId":"NCT03794258","phase":"PHASE2","title":"Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection","status":"WITHDRAWN","sponsor":"Humanity & Health Medical Group Limited","startDate":"2019-05-01","conditions":"HCV Infection","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CDI-31244 (non-nucleoside inhibitor or NNI)","CC-31244"],"phase":"phase_2","status":"active","brandName":"CDI-31244","genericName":"CDI-31244","companyName":"Cocrystal Pharma, Inc.","companyId":"cocrystal-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CDI-31244 is a small molecule inhibitor targeting the SARS-CoV-2 main protease. Used for Treatment of COVID-19.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}